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Nearly all cancers are linked by the inexorable phenotype of metastasis as malignant growths have the capability to spread from their place of
rigin to distant sites throughout the body. While different cancers may have various propensities to migrate towards specific locations, they are
ll linked by this unifying principal. Unlike most neoplasms, leukaemia has inherent cell motility as leukocytes are required to move throughout
he vascular system, suggesting that no mutations are required for anchorage independent growth. As such, it seems likely that leukaemias
re inherently metastatic, endowed with the deadliest phenotype of cancer simply due to cell of origin. This article presents the biology of
etastasis development and how leukaemia cells are inherently provided these phenotypic characteristics. It is then proposed how clinicians
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ay be able to exploit the motility of leukaemia and metastatic emboli of other cancer types through an approach known as sonodynamic
herapy (SDT), a treatment modality that combines chemotherapeutic agents with ultrasound to preferentially damage malignant cells. As
xperimental evidence has indicated, SDT is a promising therapeutic approach in need of clinical testing for further validation.
 2014 The Author. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
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.  Introduction
The heterogeneity and extent of diversity among known
ancer types is truly immense. Even within a given cancer
ype, there are various histologies, aberrant biochemical path-
ays and mutations that permeate a truly unique disease for
n individual patient. However, all cancers are linked by the
nexorable phenotype of metastasis. In other words, each can-
er has the capability to spread from its place of origin to
istant sites throughout the body (with exception to some
rain cancers). While such cancers may have various propen-
ities to migrate towards specific locations, they are all linked
y this unifying principal. In fact, more than 90% of patient
ortality due to cancer is a direct consequence of metastatic
rogression [1]. Other than aberrant cell proliferation, there
s not a single more unifying phenotype in cancer biology.
Cancer occurs after cells in a tissue progressively acquire
berrant mutations to produce progeny with uncontrolled
apacities of proliferation [2,3]. This uncontrolled mito-
is produces a primary tumour which eventually undergoes
etaplasia, followed by dysplasia and then anaplasia, result-
ng in a malignant phenotype. It is this malignant phenotype
hat provides a mechanism for intravasation into the cir-
ulation, followed by extravasation to a secondary site for
umourigenesis. Such a phenomenon is referred to as metas-
asis, defined as the spread of a cancer variant from one organ
o another non-adjacent organ [4]. As opposed to invasion
hich involves the migration of cancer cells to adjacent tis-
ue, metastasis necessitates the development of cells capable
f surviving highly variable environments as they fragment
rom the primary tumour and migrate into the vasculature.
Most cancers (∼85%) are of epithelial origin, referred to
s carcinomas. Epithelial cells are normally held in place
y junctions to adjacent cells as well as the basal lamina
atrix [3]. Most epithelial cells require such attachments in
rder to survive, thereby requiring carcinomas to undergo a
eries of mutations that not only remove this need of cell
ignalling, but allow the cell to detach from the lamina foun-
ation. However, not all cancers face such an uphill battle.
eukaemia is a highly heterogenic cancer of dedifferentiated
eukocytes that causes more disease-related deaths of chil-
ren (younger than 18 years of age) than any other disease
n the United Kingdom or United States [5, Cancer Research
K]. The statistic includes all diseases, and is a sobering
eminder of the prevalence of childhood cancer, despite the
ommendable advancements in cancer therapy. Unlike car-
inomas, leukaemia has inherent cell motility as leukocytes
re required to move throughout the vascular system, suggest-
ng that no mutations are required for anchorage independent
t
a
Irowth. As such, it seems plausible that leukaemias are inher-
ntly metastatic, endowed with the deadliest phenotype of
ancer simply due to cell of origin. However, its most dev-
stating characteristic may also be exposed as a fatal flaw if
hemotherapeutic approaches are able to exploit the ease at
hich dedifferentiated leukocytes traverse the cardiovascular
nd lymphatic systems. This article will present the biology
f metastatic progression and how leukaemia cells are inher-
ntly endowed with this devastating phenotype. Finally, it is
ndicated how clinicians may be able to exploit the motil-
ty of leukaemia and metastatic emboli of other cancer types
hrough an approach known as sonodynamic therapy (SDT),
 treatment modality that combines chemotherapeutic agents
ith ultrasound to preferentially damage malignant cells.
.  The  biology  of  non-haematopoietic  metastases
Although it may seem archaic by contemporary stan-
ards, the existence of metastasis was accurately predicted by
tephen Paget in his article, “The Distribution of Secondary
rowths In Cancer of The Breast,” published in a 1889
olume of The  Lancet. In the article, Paget examined post-
ortem data that had been assembled from 735 women with
reast cancer and noted that the organ distribution of cancer
ells in these patients followed particular migratory patterns.
ue to these observations, Paget suggested that the move-
ent of malignancy is not due to chance events; rather some
umour cells (the “seed”) grew preferentially in the microen-
ironment of select organs (the “soil”) and that migration
o secondary sites resulted only when the appropriate seed
as implanted in its suitable soil [6]. Paget’s assertion that
he microenvironment plays a critical role in regulating the
rowth of metastases has since been supported by numerous
xperimental studies; a remarkable insight for the time that
as since dramatically improved the understanding of cancer
iology.
In order for normal cells to transition into malignant
otency, there are several crucial aberrations that need to
ccur. Such characteristics include mitosis in the absence
f external growth stimulatory signals, substantial growth in
pite of exogenous inhibitory signals, angiogenesis (exclud-
ng various haematological malignancies), the potentiation
f cell immortalization, and finally, the capacity of inva-
ion and metastasis [2]. This is typically the last step in
alignancy (Fig. 1A), and is the phenotypic characteristichat kills most patients [7]. It should be noted that there is
 considerable difference between invasion and metastasis.
nvasion refers to the ability to thrust aside and displace
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Fig. 1. The pathogenesis of cancer. (A) The steps by which mutations convert normal tissue into cells of metastatic potential. The last step of carcinomas
and sarcomas is typically a series of acquired mutations that confer migration to distant sites (metastasis). (B) The progression of metastatic emboli requires
that cells from the primary tumour acquire enough mutations to fragment off, and survive the heterogeneity of the circulatory system. Once the cells reach a
secondary site, they must find the environment suitable for developing a subsequent tumour. (C) A metastatic cancer cell can cross the endothelial cell layer of
a blood vessel during intravasation to gain access to the circulatory system. This vasculature highway enables the cell to find another suitable environment in
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op image courtesy of [3]. Bottom left image courtesy of [8]. Bottom right 
djacent tissues, while metastasis is the fragmenting of
umour cells from a primary tumour that enables migration
o secondary sites via  the circulatory system [3,8]. In other
ords, primary tumours invade adjacent tissue systems, while
econdary tumours invade distant tissue systems through the
ettlement of migratory emboli. Metastasis of solid tumours
onsists of five consecutive steps which will be described
n detail: invasion and migration, intravasation, circulation,
xtravasation, and finally, the combination of colonization,
roliferation, and angiogenesis at the secondary tumour site
Fig. 1B and C). These steps will later be compared to the
nherent metastasis of leukaemia to denote similarities and
ifferences in migratory patterns.
It should be noted that while metastatic spread through
he cardiovascular or lymphatic systems are the most com-
on migratory routes, cells can also move in a transcoelomic
anner in which the spread of a malignancy into body cav-
ties can occur via  seeding the surface of the peritoneal,
leural, pericardial, or subarachnoid spaces. Examples of
ranscoelomic activity include ovarian tumours that spread
ransperitoneally to the surface of the liver, as well as
esothelioma and primary lung carcinomas migrating
hrough the pleural cavity, causing malignant pleural effu-
ion [9]. In addition, the accidental transfer of cancer cells
uring surgical intervention is an artificial form of metastasis
hat presents an ever posing threat to patients in the clinic
2].
i
c
mourtesy of [2].
.1.  Invasion  and  migration
In order for a primary tumour to become metastatic, neo-
lastic cell dissemination to different organs is an inherent
ecessity. Dissemination is a complex cell motility phe-
omenon, requiring the molecular coordination of protrusion,
hemotaxis, invasion, and contractility; all in an effort to
chieve directed cell migration. The epithelial-mesenchymal
ransition (EMT) is an important early step in carcinomas
or the conversion of primary tumour cells into a migratory
opulation that is capable of systemic metastasis [9,10]. In
ffect, epithelial cells lose their cell polarity and cell–cell
dhesion as they transform into mesenchymal stem cells
MSCs), gaining migratory and invasive properties of such
ell types. When the cell reaches its target secondary site,
t then reverts using the mesenchymal–epithelial transition
MET), allowing the carcinoma to seed in a distant organ.
lthough the EMT/MET transition is a natural phenomenon
ound in wound healing, it is aberrantly overused in tumouri-
enic epithelial cells [11–14].
In order for metastatic cells to traverse the distance
etween the epithelial lining and the endothelium leading
p to intravasation, the development of substantial motil-
ty stands out as a necessity. High resolution multiphoton
maging of tumours in  vivo  has shown that malignant
ells use both collective and single cell motility in their
igration to the circulatory system. Breast carcinoma cell
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otility is characterized by solitary amoeboid movement at
peeds significantly higher than other types of cell motil-
ty (∼4 m/min) [10]. The explanation to such high rates of
ravel is truly profound; invasive tumour cells form pseudo-
odia in  vivo  in response to epidermal growth factor (EGF)
ecreted by tumour-associated macrophages, as part of the
ancer cell/macrophage paracrine loop described in breast
arcinomas [20,21]. Filamentous (F)-actin rich pseudopodia
re the defining morphological feature of fast moving amoe-
oid cells and are involved in chemotaxis to direct neoplastic
ells towards blood vessels before intravasation [10].
.2.  Intravasation
Once metastatic carcinoma cells successfully detach from
heir epithelial lining, they must gain access to the circula-
ory system if they are to invade nonadjacent organ systems.
hile proteases degrade the extracellular matrix (ECM),
stablishing a basis for invasion, the tumour cells themselves
ust have the capacity to migrate down this path to reach
he endothelial lining of the circulatory system. The macro-
olecular explanations for the acquisition of cell motility
re rather straightforward as the remodelling of the actin
ytoskeleton, along with the formation and dissolving of
dhesion complexes are integral to generating this novel phe-
otype. As a result of the EMT-MET transition, the malignant
ells are capable of developing lamellipodia that stretch in
he moving direction [2,23]. On the front end of the cell,
ntegrins build new focal contacts between ECM and lamel-
ipodium, while the connections on the end are dissolved.
y this approach, the cell moves and continuously secretes
roteases on its march to the endothelium. On the edge of
 lamellipodium, spiky structures known as filopodia also
orm by the reorganization of microfilaments [23]. The for-
ation of filopodia is vital for cell motility as they form focal
dhesions with the substratum, linking it to the cell surface.
igrating cells almost always display filopodia as they are
nvolved in the sensation of chemotaxis, resulting in changes
o directed locomotion [24].
Although cell motility is integral for intravasation, it is
ot until the malignant cells break through the lumen of lym-
hatic or blood vessels that this step of metastasis is complete.
alignant cells can either directly or indirectly reach the car-
iovascular system, as metastatic spread can initially begin
n the lymphatic system. While classical cancer biology typ-
cally focuses on intravasation of haematological origin, it
as been elucidated that lymphatic spread is just as relevant
o metastasis. Integral to the purification of blood, the lym-
hatic system collects the interstitial fluid, moving the fluid
hrough the lymph nodes and lymphatic vessels until it returns
o cardiovascular circulation. It has even been proposed that
arcinomas often spread initially via  the lymphogenous sys-
em, whereas sarcomas tend to spread via  the haematological
ystem [30]. This may be due to the fact that the penetration of
ymphatic vessels is easier due to the absence of a continuous
b
a
t
lgy/Hematology 94 (2015) 149–163
asement membrane and a coating layer of pericytes, as well
s their weak inter-endothelial connections [30].
.3.  Circulation
Cells that manage to break through the endothelium of the
irculatory system gain access to a vast network of vessels,
ubstantially increasing the likelihood of secondary tumours.
nder normal physiological conditions, most cells activate a
pecial form of apoptosis known as anoikis in the case they
re unable to adhere to solid substrate or other cells (Fig. 2)
31]. In fact, cancer cells that are still anchorage dependent
t the time of entering the circulation have anoikis activated,
hereby destroying the cells [32]. While most cells would not
urvive and proliferate in the heterogeneous environment of
he vasculature due to the lack of a solid substrate, malig-
ant cells typically acquire enough mutations to become
noikis resistant (Fig. 2). In addition, if malignant cells are
ot yet independent of exogenous growth factors which are
ecreted by stroma cells, apoptosis is likely to be induced
ue to the absence of such growth factors in circulation
3].
Even when malignant cells have acquired these advan-
ageous adaptions, they are still highly vulnerable in the
asculature. In smaller vessels, such as the arterioles or
apillaries, high shear forces often occur. This can cause
ignificant damage to neoplastic cells, as they do not have
he unique cytoskeletal structure of erythrocytes that per-
its such mechanical stress [3]. Such forces are likely to
e a primary reason for metastatic inefficiency. Further,
he heterogenic environment of circulation, characterized
y extremely high concentrations of oxygen and lympho-
ytes, substantially impair the progression of malignant cells
2,3]. Therefore, the presence of these adverse conditions
ctually provides a breeding ground for particularly aggres-
ive and resistant cancer cells due to selection pressures [2].
alignant cells antagonize the potentially toxic conditions
f the vasculature by forming microemboli, an aggrega-
ion of tumour cells with thrombocytes and erythrocytes
7]. The formation of microemboli is mainly due to tissue
actor, a protein highly expressed in malignant carcinoma
ells, but not on benign tumour or healthy epithelial cells.
issue factor interacts with special proteins in the plasma
o activate thrombin which converts fibrinogen into fibrin,
hereby resulting in cell conglomeration [7]. The importance
f metastatic emboli has been analyzed in knock-out mice
hich lacked specific components of the clumping-cascade
33]. Melanoma cells were administered intravenously (i.v.)
nto the knock-out mice to assess metastatic efficiency. In
omparison to the control group, metastasis was decreased
y >90%. By shielding neoplastic cells from the unsta-
le environment of circulation, emboli formation becomes
n integral mechanism for the survival of cancer metas-
ases as they continue their migration towards a secondary
ocation.
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Fig. 2. The anoikis cascade and development of resistance. When detached from ECM, normal cells induce anoikis through both intrinsic and extrinsic
pathways. Upon cell detachment, FAS and FasL are upregulated and FLICE-like inhibitory protein (FLIP) is downregulated, resulting in the activation of
caspase-8. This is followed by activation of caspase-7 and caspase-3. Loss of cell adhesion also activates proapoptotic Bcl-2 proteins (Bik, Puma, Bad, Noxa,
Bmf, Bid, Bim, Bax, and Bak) that inactivate antiapoptotic Bcl-2 proteins (Bcl-2, Bcl-xL, Mcl-1), thereby inducing mitochondrial membrane permeabilization
through apparent Bax/Bak oligomerization. Such activity causes mitochondria to release cytochrome c, activating caspase-9 and subsequently caspase-3.
Smac/DIABLO is released and inhibits XIAP (inhibitor of apoptosis) perpetuating caspase-3 activation. Once this occurs, anoikis is inevitable. However,
increased FLIP expression in malignant cells inhibits the extrinsic pathway. Further, oncogenic expression induced by epidermal growth factor receptor (EGFR)
and hypoxia often seen in neoplastic cells downregulate Bmf and Bim, inhibiting the mitochondrial pathway in suspended cells. In this regard, cells acquire
anoikis resistance, substantially increasing the likelihood of anchorage independent growth.
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.4.  Extravasation
Eventually, partially due to chemokine signalling, par-
ially due to trial and error, the metastatic cells approach an
rgan that is suitable for secondary growth. Before reaching
hat organ, the cells must find a way to exit the circulatory
ighway. If cancer cells survive the adverse conditions in the
essels and reach larger venous blood vessels, they are car-
ied further by the bloodstream until they enter the capillary
etwork of the lungs. There is a high probability that the can-
er cells will become entangled in the capillary system of
he lungs due to the sheer difference in size between malig-
ant cells and the small vessels that must be successfully
raversed. For comparison, cancer cells are often ∼20 m
n size, in relation to the capillaries that are ∼3–8 m [2].
nlike erythrocytes that are designed to meander through
he narrow passages, malignant cells are not very elastic and
ften form microthrombi. Therefore, the probability that the
etastatic emboli will become lodged in the arterioles is very
igh. It is nothing short of miraculous that any malignant
ells are able to successfully traverse the circulatory system.
p
r
nnfortunately for the patient, even a highly unlikely event
ecomes probable when enough cells reach this metastatic
tate.
In addition, the ever resilient cancer cells have mecha-
isms to greatly increase the odds in their favour. It is likely
hat neoplastic cells nearing the lung capillaries discard a
remendous amount of cytoplasm in order to form smaller, but
till viable cells that are capable of passing through the small
ascular network. It has also been elucidated that some cancer
ells can avoid the capillary network by using arterial–venous
hunts, bypassing the capillaries altogether [7]. Either way,
hen malignant cells leave the lung capillaries and reach
he general arterial vessels, they have access to a substantial
ariety of body tissue.
Once the cells have reached a favourable secondary site,
xtravasation will occur in two different ways. One possibil-
ty is that neoplastic cells begin proliferating in the lumen of
 vessel. The rapidly growing tumour will eventually com-
romise the vessel wall, thereby providing an accessible
oute into the tissue [7]. The second possibility for malig-
ant cells to penetrate an organ is similar to intravasation
154 M. Trendowski / Critical Reviews in Oncology/Hematology 94 (2015) 149–163
Fig. 3. Leukocyte extravasation due to an immune response. The entry of leukocytes into tissue due to an immune response is controlled by a cascade of
molecular interactions. Upon recognition of disturbance or pathogens, resident macrophages in the affected tissue release cytokines such as IL-1, TNF and
chemokines. IL-1 and TNF enable the endothelium of blood vessels near the site of infection to express cellular adhesion molecules, including selectins.
Circulating leukocytes are localized towards the site of injury or infection due to the presence of chemokines. The selectins initiate the tethering of leukocytes
to the endothelial cell surface, initiating rolling adhesion. Leukocytes roll along the blood vessel wall and sense activating chemokines, which are deposited on
the endothelial cell surface. This interaction results in the activation of leukocyte integrins, which bind members of the immunoglobulin superfamily (Ig-SF)
that are responsible for mediating firm adhesion. Such activity enables directed migration on the endothelial cell surface.
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nd includes the degradation of endothelium and basement
embrane through proteolytic enzymes. Leukocytes also
ave the ability to extravasate in great quantity over a short
eriod in order to combat inflammation and infection [35].
n the course of this process known as diapedesis, leuko-
ytes adhere via  selectins to the endothelium and perform a
orm of rolling adhesion to interact with endothelial cells,
hich in turn enables the passage of leukocytes. This is due
o the fact that carbohydrate ligands on the circulating leuko-
ytes bind selectin molecules on the inner wall of the vessel
ith marginal affinity. Such activity enables leukocytes to
low down and begin rolling along the inner surface of the
essel wall (Fig. 3) [34]. During this rolling motion, tran-
itory bonds are formed and broken between selectins and
heir associated ligands, causing leukocyte motion to halt.
iapedesis involves a variety of molecules including LFA- + ICAM-2, CD3 + ICAM-1, as well as PECAM (CD31),
nd the complete process takes place in less than a minute
35].
t
e
t.5.  Colonization,  proliferation  and  angiogenesis  at  the
econdary  tumour  site
Now that the metastatic cells have successfully reached
n ideal secondary location, they must quickly begin altering
he extracellular environment within the organ to establish
avourable conditions for a proliferating tumour. The new
icroenvironment typically does not provide the same sur-
ival and growth factors as the original tissue, which enabled
he primary tumour to proliferate [7]. Without the special
hysiological factors of the original site, many metastasizing
ells die or reside without proliferation as micrometastases.
n fact, the amount of senescent micrometastases in can-
er patients usually exceeds the amount of micrometastases
hat grow to a detectable size [2]. The detection of keratin
rofiles typically seen with epithelial cells in mesenchymal
issue provides evidence for micrometastases. This technique
nables physicians to track down single cell micrometas-
ases amongst 105–106 surrounding mesenchymal cells [7].
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t has been confirmed that the EMT which takes place at
he beginning of metastatic invasion is reversed during col-
nization (referred to as MET) [36]. This transition enables
etastasized tumour cells to adopt their original epithelial
haracter. As suspected by Paget years ago, considerable
vidence suggests that that molecular factors present in spe-
ific organs can influence whether or not metastatic cells will
nd the environment favourable for colonization [37]. Breast
nd prostate carcinoma cells often metastasize to bone due
o favourable interactions between the malignant and bone
ells (osteoblasts and osteoclasts in particular) [38]. This
rototypical seed and soil situation is also found in colon
arcinomas and other cancers that metastasize to the liver, as
pecific growth factor receptors needed for sustained prolif-
ration are readily available in the hepatic microenvironment.
After initial colonization and proliferation of secondary
umours, there needs to be development of an adequate blood
upply that can sustain the ever increasing metabolic activ-
ty of the tumourigenic growth. Since there are usually not
nough adjacent blood vessels to recruit, tumours simply
ake their own. In regard to cancer biology, angiogenesis is
he formation of new blood vessels in the direction of a tumour
o provide it with nutrients and to remove metabolic waste
roducts [39]. Commonly seen in primary tumours, angio-
enesis becomes just as integral to secondary malignancies
hat exceed the natural blood supply of their microenviron-
ent.
.  The  inherent  metastasis  of  leukaemia
Although cancers found more commonly in adults have
articularly high mortality rates (pancreatic, liver, and lung),
hey take much longer to develop malignancy than child-
ood cancers. In fact, many adult carcinomas require years
f incubation before enough mutations have been acquired
or detectable symptoms to become apparent [5]. By con-
rast, leukaemia, the most prolific childhood cancer in the
nited Kingdom and the United States often only takes a
ew months to spread throughout the patient. While it is
rue that leukaemias are often found in adults, many of these
ases are in the form of secondary leukaemia, an unfortunate
ide effect of prior chemotherapeutic intervention [40,41]. In
act, leukaemia has the highest proportion of child vs.  adult
alignancy rates than any other cancer [5]. It also should
e noted that many of those adults fall within the 18–30
ear old range, still substantially younger than most cancer
ncidence.
With such a high proportion of young individuals being
iagnosed with leukaemia, there must be some phenotypic
haracteristics that set the haematological malignancy apart
rom other cancers. This becomes apparent when the nature of
eukocytes, the blood cells that dedifferentiate into leukaemic
alignancy, is taken into consideration. By default, leuko-
ytes have substantial mobility, circulating the vasculature in
atrol or in response of pathogenic disturbance. In a manner
o
f
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imilar to transformed malignant cells, leukocytes are also
apable of amoeboid migration, meandering their way
hrough the ECM to reach a site of infection or inflammation
34,35]. Therefore, the first two steps of metastasis (invasion
nd migration, intravasation) are unnecessary as leukocytes
re naturally found in systemic circulation, and have the capa-
ility to migrate towards endothelial tissue. The classes of
eukocytes are incredibly diverse by nature, as a result of
eing either of myeloid (monocytes and macrophages, neu-
rophils, basophils, and eosinophils) or lymphoid (T-cells,
-cells, and natural killer, NK cells). Consequently, leuko-
ytes give rise to a profound heterogeneity of cancers [42,43].
s expected, the demands of such a diverse cell type are sat-
sfied by an ever-present population of haematopoietic stem
ells (HSCs). Cancers can be thought of as cells that have
een reprogrammed to a dedifferentiated state, marked by
ene expression typically reserved for embryonic or adult
tem cells. As will be explained, this abundant population
f stem cells makes blood cells particularly prone to cancer
athogenesis.
In addition, this review has already established that it
s necessary for leukocytes to maintain an innate form of
xtravasation, as they need such characteristics to elicit a
apid immune response [34,35]. Being of the haematopoietic
ineage, leukaemias do not require mutations to avoid anoikis,
roviding further evidence that leukocytes require fewer
utations to become malignant. Taking all of these pheno-
ypic characteristics together, it becomes more apparent why
eukaemias are the most prevalent childhood cancers. Based
n the cancer biology of other cell types, it can be inferred that
eukaemia is endowed with inherent metastatic potential. In a
ense, leukaemias often require fewer mutations than cancers
f other cell types to spread throughout the patient. It is this
nherent metastasis that separates leukaemia from any other
alignancy.
.1.  Migratory  patterns  of  leukaemia
If leukaemia was inherently metastatic, it should have
haracteristic migratory patterns as found in other cancers.
uch an answer requires only a scalpel and patience (as well
s patients). In fact, autopsy reports describing leukaemia
ortality have long been established in the clinical setting
44,45]. In most cases, it appears that leukaemia has a simi-
ar seeding frequency of the skin, breast, trachea, diaphragm
nd all other muscles. Due to their cell type of origin, the
ighest incidence of metastasis is found in the lymphatic
ystem (lymph nodes and spleen). The excess of metas-
ases at specific sites do not cluster in topographical areas
r in anatomical systems, with the exception of metastases
n the central nervous and endocrine systems (acute lym-
hoid leukaemia, ALL). From the unique migratory patterns
f ALL, it can be inferred that soil specificity may account
or the higher than expected occurrence of metastases in
he noted organs for a specific leukaemia. Chronic lym-
hoid leukaemia (CLL) shows an excess of metastases in
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ll lymph nodes, kidneys, adrenals and the heart. The unique
eeding of CLL suggests a lymphatic route of dissemina-
ion, as opposed to a cardiovascular spread of malignant cells
44].
While more common leukaemias such as ALL and CLL
ave been categorized for years, the unique dissemination
atterns of NK-derived leukaemias were categorized much
ater [46,47]. Pathologically, NK leukaemias show vari-
ble cytological appearances, with frequent angiocentricity
angioinvasion and angiodestruction) associated with zonal
ecrosis of affected areas. Most cases occur in the nasopha-
ynx and upper aerodigestive tract. However, occurrence in
on-nasal sites such as the skin, gastrointestinal tract and
estes is also observed [51]. While NK leukaemias have
pparent differences in their migratory patterns, they share a
ommon trait with other haematological malignancies of leu-
ocyte origin in the formation of aberrant skin lesions (cutis)
46,47]. Leukaemia cutis refers to the infiltration of trans-
ormed leukocytes or their precursors into the skin resulting
n readily identifiable cutaneous lesions. Patient examina-
ion typically reveals multiple hyperpigmented nodules and
laques involving the face, trunk, and extremities. A diagno-
is of leukaemia cutis generally portends a poor prognosis, as
t strongly correlates with additional sites of extramedullary
nvolvement [47]. Unlike most cancers, leukaemia has the
apability to blanket the dermal layers with cutaneous
esions, providing a profound visual example of its metastatic
xtent.
.2.  Uncontrolled  haematopoietic  stem  cells  perpetuate
eukaemia
It has been well established that endogenous stem cell
opulations are often a foreground for tumorigenesis [7].
s is seen in leukaemia, haematopoietic stem cells (HSCs)
lay a monumental role in malignancy development. Dur-
ng haematopoiesis, the progenitor HSCs receive a complex
rray of transcription factors and growth signals to differ-
ntiate into all known existing blood cells [42]. Within this
ystem, HSCs give rise to either the lymphoid or myeloid
ineage as subsequent cell progeny are directed by fur-
her differentiation steps to give rise to the desired cell
ype [48]. However, when improper signalling or mutations
ccur within HSCs, the likelihood of leukaemia pathogene-
is is dramatically increased [49]. Normal haematopoiesis
equires complex interactions between the bone marrow
icroenvironment (the stem cell niche) and HSCs. These
nteractions are critical for the maintenance of normal HSC
ctivity, and deregulation of this intricate system aberrantly
nfluences HSC self-renewal [49,50]. If this self-renewal
s left unchecked, progression into leukaemic stem cells
LSCs) that also possess limitless self-renewal may be gen-
rated in the stem cell population, hijacking the homeostatic
echanisms necessary for proper differentiation (Fig. 4A)
49,50]. LSCs are extremely resilient as they take refuge
ithin the sanctuary of the niche during chemotherapy,
c
r
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nd consequently contribute to eventual disease relapse
43].
Such deregulation of HSCs is apparent in acute myeloid
eukaemia (AML), a leukaemia that has significant clinical
elevance due to its prevalence in patients. AML is the sec-
nd most common leukaemia diagnosed in both adults and
hildren, with a five year survival rate of only 24% [5]. As
uch, HSC deregulation leading to AML is a common phe-
omenon in the clinic, and has been meticulously studied
n order to further elucidate the pathogenesis of the dis-
ase. As for many haematological malignancies, AML has
een extensively characterized as a cell autonomous disor-
er, as the genetic events leading to transformation of the
ormal haematopoietic cell are found within that cell, and
re both necessary as well as sufficient for leukaemic devel-
pment [49,50]. Aberrant fusion proteins, such as MLL-AF9
r MLL-ENL1 that are expressed as a consequence of chro-
osomal translocations are typically present in leukaemic
lasts derived from patients with AML [43]. Introduction of
he subsequent alleles into normal bone marrow cells per-
etuates AML in murine models of disease, validating their
ncogenic properties [50]. This constructed AML accurately
ecapitulates the human disease phenotype, including hall-
ark stem cell properties such as the ability to consecutively
eplate on methylcellulose in the absence of stroma, and the
bility to confer an AML phenotype that can be transplanted
n vivo  [50].
Although all AML cells are thought to harbour the cell-
utonomous mutations that are found in its pathogenesis,
he subpopulation of AML cells referred to as LSCs are
esponsible for the long-term repopulating potential as well
s the ability to propagate and maintain the AML phe-
otype [51,52]. It has been estimated that as few as one
n a million AML cells possess leukaemia initiating activ-
ty [51]. Therefore, AML has a hierarchical organization
imilar to that of normal haematopoiesis in which there
s a rare subpopulation of cells with limitless self-renewal
otential that give rise to progeny that lack such potential
51,52]. LSCs in certain types of murine AML (induced
y MLL-AF9, 2 MOZ-TIF2, 2 MOZ-TIF3 or MLL-ENL1)
ave characteristics of progenitor cells with phenotypic
haracteristics similar to normal granulocyte/macrophage
recursors [53]. The leukaemia-initiating cells are more
ature than HSCs, but have acquired limitless self-renewal
hrough oncogenic transformation, leading to the activation
f essential stem cell genes [53,54]. These observations are
ntriguing, as it suggests that only a relatively few amount
f AML cells are responsible for perpetuating metastatic
isease in the patient. This concept opens up the idea
f finding therapeutic approaches that specifically target
eukaemic progenitors, an approach that has been under
onsiderable investigation (Fig. 4B) [53,55]. If treatments
an be successfully devised, the malignant cells actually
esponsible for maintaining leukaemia cell populations will
e eradicated, theoretically neutralizing disease progres-
ion.
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Fig. 4. The leukaemic stem cell model and the need for novel therapeutic approaches. (A) The LSC model proposes that leukaemic blasts originate from a
common primitive progenitor that has the capacity to self-renew, akin to normal haematopoiesis. Therefore, such cells are required for maintaining leukaemia cell
populations, providing a compelling therapeutic target. (B) Conventional therapies for leukaemia have been designed to eliminate leukaemic blasts. However,
these regimens are not as responsive to the LSC population, which eventually recapitulates the disease with drug resistant progeny. The ability to design
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.3.  Richter’s  syndrome:  evidence  of  lymphoid
eukaemia  acting  as  lymphoma  metastases
Although leukaemias and lymphomas are both derived
rom leukocytes, the haematological malignancies are pro-
oundly different in that leukaemias are inherently “liquid
ancers” that do not form solid tumours, while lymphomas
orm primary tumours in a variety of organ systems. Lym-
homas refer to a group of haematological malignancies that
evelop from lymphocytes, and form solid tumours primar-
ly in the lymphatic system, but can also form in other areas
f the body [56,57]. These haematological malignancies are
ypically broken down into Hodgkin’s lymphoma (HL) and
on-Hodgkin’s lymphoma (NHL), the main difference being
odgkin’s lymphoma is characterized by Reed-Sternberg
ells (enlarged B-lymphocytes that are either multinucle-
ted or have a bilobed nucleus) [56]. Further characterization
f HL can also include “mummified” erythrocytes (com-
act nuclei, basophilic cytoplasm, and no nucleoli), as well
s popcorn cells (small cells with hyper-lobulated nuclei
nd small nucleoli) in nodular lymphocyte predominant
odgkin’s lymphoma (NLPHL) [56]. As with most solid
umours, lymphomas have the potential to metastasize once
nough mutations have been acquired at the primary tumour
ite, and secondary sites can range anywhere from the brain
o the heart [56–58].
Due to the similarities between leukaemias and metas-
ases from solid tumours, it may be possible that in some
ases, leukaemias act very similar to lymphoma metastases,
n which further mutations enable the malignancy to seed
B
a
bts for leukaemias that have been confirmed to rely on LSCs, such as AML.
n an appropriate environment, akin to carcinomas acquir-
ng additional mutations to form tumours at secondary sites.
ince lymphomas are strictly of the lymphoid lineage, it
hould be the case that only lymphoid leukaemias (ALL,
LL, hairy cell leukaemia, T-cell prolymphocytic leukaemia,
nd adult T-cell leukaemia) are capable of being transformed
nto lymphomas. Further, transformed leukaemias should
ave characteristics similar to lymphomas, and have mutual
eeding preferences.
Richter’s syndrome is a transformation that converts B-
LL and hairy cell leukaemia (can be considered a subset
f CLL) into fast-growing diffuse large B cell lymphoma
DLBCL), and in some cases HL, with a frequency of
bout 5–10% in patients [59–61]. In the majority of these
atients, lymphoma clones are perpetuated by transforma-
ion of original CLL clones, but some form a separate and
ndependent neoplasm [59]. Patients often present with a
apid clinical deterioration, and average survival is typi-
ally between 5 and 8 months post-diagnosis [62]. While
he conversion from CLL to lymphoma has not been well-
haracterized, typical karyotype aberrations have been noted,
uch as trisomy 12, deletion at 13q14, deletions at 11q22-q23
nvolving the ATM gene, and deletion at 17p13 involving p53
59–61]. All of these aberrations are associated with B-cell
ymphoma progression [63–66], suggesting that the genetic
efects are likely involved in the transformation. Further,
ichter’s syndrome cells have seeding sites very similar to
-cell [65,66] and Hodgkin’s lymphoma [67,68], providing
dditional support that CLL can be transformed to a tumour-
earing lymphoma under appropriate circumstances.
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Although it is a relatively rare phenomenon, Richter’s
yndrome demonstrates that leukaemic cells have the poten-
ial to form solid tumours after appropriate mutations.
lthough there is a clear distinction between leukaemias
nd lymphomas, the fact that CLL can be transformed
nto a lymphoma demonstrates that leukaemias can seed
t locations, thereby eliminating the most notable differ-
nce between the haematological malignancies. Therefore,
ymphoid leukaemias can be viewed as having very simi-
ar characteristics to metastatic lymphoma cells, having the
ropensity to form tumours at distant sites once enough aber-
ant mutations have been acquired.
.  Exploiting  the  inherent  metastasis  of  leukaemia
Throughout this article, similarities between solid tumour
etastases and leukaemias have been proposed in order to
uggest that leukaemia cells are inherently metastatic. This
omparison has been made for a very practical reason; if
etastatic emboli are comparable to leukaemias, perhaps
he unique phenotypic characteristics that link the malignant
rowths can be exploited to improve current chemotherapeu-
ic approaches. That is, use the most devastating phenotypic
haracteristics of the malignancy to develop novel therapeu-
ic methods that specifically target and damage circulating
ancer cells. Such an approach could not only significantly
mprove leukaemia chemotherapy, but also treatments for
arcinomas that commonly metastasize and form secondary
umours. After all, it is the metastatic phenotype of cancer
hat subdues most patients.
This form of targeted chemotherapy may be achieved by
onodynamic therapy (SDT), a novel treatment modality that
ses ultrasound in combination with specialized chemother-
peutic agents known as sonosensitizers to preferentially
amage malignant cells. It has been shown in numerous
xperiments that ultrasound preferentially damages malig-
ant cells based on the size differential between such cells
nd those of normal histology [69–71]. This is particularly
mportant for leukaemia and other metastatic diseases, as the
alignant cells will be in close proximity to normal blood
ells. By targeting the inherent size differential of the malig-
ant cells in comparison to the normal cells in circulation,
DT asserts itself as a therapeutic approach that is both effec-
ive and specific. The size differential between malignant
nd normal cells can be dramatically increased through the
se of sonosensitizers that specifically target malignant cells,
hereby amplifying the preferential damage of ultrasound
69].
SDT has also been shown to be particularly effective
gainst drug resistant cell lines. One of the most cited
hortcomings of chemotherapy in clinical practices is drug
esistance acquired by tumours. SDT has been shown to
everse this potent defense mechanism in human leukaemia
ultidrug resistant cell line K562/A02 [72]. Reversal of drug
esistance has also been observed in HepG2/ADM human
i
t
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ultidrug resistant hepatocellular carcinoma cells, demon-
trating the versatility of SDT [71]. Sonosensitizers often
ttack cells through multiple mechanisms, creating a poten-
ial synergistic effect when agents of different classes are
sed in combination [69]. Being able to develop treatment
egimens in which the synergistic effects of different sonosen-
itizers are applied can have profound clinical utility. Such
reatments could substantially amplify the capability of ultra-
ound to preferentially damage malignant cells in order to
ecrease the rate at which drug resistance is observed.
In order to use SDT in the clinical setting, effective meas-
res need to be devised by which to administer ultrasound and
hemotherapeutic agents to patients. Seeing that SDT has yet
o be tested in the clinical setting, there has been no analysis
s to how this treatment modality could be practically applied
o patients. Although SDT fundamentally relies on an ultra-
ound system, there are a variety of ways in which sonication
an be delivered. A potentially important approach that takes
ull advantage of the inherent metastasis of leukaemia is
 form of extracorporeal blood sonication (EBS) in which
lood is drawn out of the body, as in hemodialysis, and then
onicated before it reenters the patient. This approach will be
escribed in detail, along with using established sonication
echniques currently employed in the clinic for the treatment
f prostate carcinoma and calcified deposits. In addition,
ytochalasin B, a sonosensitizer that could have immediate
linical importance, is also characterized. It is hoped that such
fforts will convince academics and clinicians of how the
nique characteristics of metastatic disease can be exploited
o improve chemotherapeutic approaches in many clinical
ontexts.
.1.  Extracorporeal  blood  sonication
Ultrasound inevitably loses some of its intensity as it trav-
ls through the human body. If there was a way to remove
alignant cells from the body so they could be treated in
n extracorporeal environment, there would be no sound
nhibitors protecting such cells from the preferential damage
f SDT. Although such an approach is unfeasible for most
alignancies, leukaemia is unique in that it does not form
 primary tumour site. Rather, it flows through the blood,
longside normal cells as it slowly overcomes the natural
efenses of the immune system. However, its most benefi-
ial asset can be exploited to become a profound fatal flaw.
ince most leukaemias are localized in the blood, it would
e rather straightforward to draw the malignant cells out of
he body through dialysis. While dialysis is typically used
n patients to act as an artificial replacement for lost kidney
unction due to renal failure, it could just as easily be used
o treat leukaemia in an extracorporeal setting. Sonosensi-
izers would be injected i.v. with some time passing before
njection and sonication. The patient would then undergo a
ypical hemodialysis procedure in which blood is pumped
utside of the body, thereby removing the natural sound bar-
iers of human anatomy. There would be nothing standing
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n the way between the malignant cells and the ultrasonic
aves that are able to inflict considerable preferential dam-
ge. In effect, this SDT procedure allows an in  vivo  setting
o become almost in  vitro. Since the in  vitro  studies of SDT
ith leukaemia have yielded impressive results [72–75], this
ay be the most effective way to administer ultrasound to
uch patients.
However, the sound intensities used in EBS will likely
ave to be carefully monitored. There is very little standing
n the way between the blood and the high intensity ultra-
ound being administered. While normal erythrocytes and
eukocytes are more resistant to SDT, they are not invul-
erable. Sufficient sound intensities will cause just as much
amage to these cells as the malignant cells that are within
lose proximity [76]. Therefore, the sound intensity used in
BS might have to be considerably reduced. Nevertheless, it
till provides the most direct route for sonicating leukaemic
lasts that are the hallmark of leukaemia pathology. Fur-
her, there have been ultrasonic probes already devised that
ould be used to sonicate bone marrow containing aleukaemic
ells as well the LSCs shown to be the driving force behind
any haematological malignancies, as will be described in
he following section. The combinatorial approach of EBS
ith such probes could provide a method to comprehensively
onicate almost all areas where metastatic disease (including
arcinomas) may reside.
.2.  Using  focused  ultrasound  to  target  leukaemic  stem
ells in the  bone  marrow  and  solid  tumours
Although EBS is a potential avenue for treating
eukaemias and solid tumour metastases, sonication of the
lood would yield little benefit for other cancers that are
ften concentrated at a primary tumour site. Further, patients
ypically have leukaemia cells that remain trapped in the
one morrow, particularly LSCs that perpetuate blast for-
ation. In addition, aleukaemic blasts can remain in the
one marrow, severely perturbing normal production of blood
ells. Without the luxury of directly sonicating the blood that
an transport blasts and circulating LSCs to an extracorpo-
eal environment, another sonication approach needs to be
evised. One that is capable of scanning patients for concen-
rated pockets of neoplastic cells, and then sonicating these
reas with high-intensity ultrasound.
In fact, such technology already exists and could be readily
pplied in the clinic with a few minor adjustments. Ultrasonic
robes are devices capable of delivering high frequency or
igh intensity ultrasound to localized areas, and are com-
only used in the medical field for diagnostic imaging (high
requency) or even breaking up calcified kidney stones (high
ntensity). Medical ultrasonography uses a substantial vari-
ty of ultrasonic probes, and many operational systems are
vailable for testing with SDT. As an example, high intensity
ocused ultrasound (HIFU) probes are currently being used in
he clinic for extracorporeal shock wave lithotripsy (ESWL),
nd in the treatment of prostate carcinomas. The lithotripter
c
T
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sed in such procedures breaks up cell aggregates or calcified
tones using multiple focused beams of externally applied,
ocused, high intensity acoustic pulses [77–80], which could
e readily converted for SDT-mediated treatment protocols.
SWL and HIFU-mediated ablation of prostate carcinoma
an actually be seen as potential evidence of SDT efficacy, as
he methods break up concentrated deposits through inertial
avitation (the process of creating microbubbles in liquids,
uch as cellular cytoplasm), just as in SDT. The benefit of
DT over HIFU-mediated ablation resides in the fact that
DT activates chemotherapeutic agents in addition to pro-
ucing inertial cavitation, providing additional mechanisms
y which to damage malignant growths.
Due to the advances in medical imaging, it is now possi-
le to readily locate primary tumour sites, providing the basis
or sonochemotherapeutic protocols. By injecting sonosen-
itizers i.v. or subcutaneously (s.c.) at tumour aggregates
rior to treatment, ultrasonic probes can be locally applied
o the affected site, thereby allowing a potentially site-
pecified chemotherapeutic approach. Although it may not
pply directly to leukaemia, combining the drug activation of
DT with ultrasound-guided drug injection, as is performed
n endoscopic ultrasound-fine needle injection (EUS-FNI)
81,82], may be particularly beneficial for solid tumours,
ncluding mediastinal lymphomas. This is further supported
y research that indicates EUS can be used to improve the
elivery of photodynamic therapy (PDT) in porcine models
83,84], which acts by similar mechanisms to SDT. As such,
his therapeutic method has apparent clinical implications
utside haematological malignancies, as a great diversity of
ancers could be treated using this method. Further, using
ocused ultrasound to target neoplastic cells caught in the
one marrow may be a method by which to specifically target
SCs, although the preferential damage SDT elicits towards
ormal leukaemic cells still needs to be confirmed with LSCs.
t should be noted that leukaemia cells are preferentially dam-
ged in the presence of human haematopoietic stem cells
hHSCs) and normal leukocytes [73], suggesting that prefer-
ntial damage within the confines of the bone marrow (or the
lood for circulating LSCs) is feasible. The extent of neo-
lasms that can be treated through this form of SDT will
nly be determined through further preclinical and eventual
linical evaluation.
.3.  Cytochalasin  B  as  the  prototypical  sonosensitizer
By default, malignant cells have a perturbed cytoskele-
on due to the effects of dysplasia and subsequent anaplasia
7]. With so many alterations present in malignant cells, the
ytoskeleton provides an ideal opportunity for preferential
amage. Specifically, one of the most intriguing possibili-
ies is to preferentially lyse malignant cells based on their
onsiderable size differential to cells of normal histology.
his fact suggests that enlarging malignant cells to increase
heir already noticeable size difference with normal cells
ay be a method by which to attain preferential damage.
160 M. Trendowski / Critical Reviews in Oncology/Hematology 94 (2015) 149–163
Fig. 5. Effects of 1.5 M cytochalasin B on U937 cells 48 h post-administration. (A) Untreated U937 cells typically have a size distribution of 13–18 m. (B)
U937 cells 48 h after treatment with 1.5 M cytochalasin B are enlarged (19–40 m) and multinucleated. Grey arrow indicates a mononucleated cell. Red arrow
indicates an enlarged and multinucleated cell. Nuclei were visualized with Wright–Giesma stain. Photomicrographs were taken under identical conditions of
magnification (100×). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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ytochalasin B is a microfilament-disrupting agent that dis-
upts the actin cytoskeleton and inhibits cytokinesis by
nterfering with formation of the contractile ring, as well as
he development of the cleavage furrow [69]. Consequently,
he cell does not divide and an immature actin cytoskeleton
emains. However, the cell continues to form nuclei and even-
ually becomes enlarged and multinucleated (Fig. 5). Such
ells have more DNA targets, increasing the likelihood of
poptosis when combined with nucleic acid-directed agents,
s demonstrated by my laboratory with doxorubicin (DOX)
nd 5-flourouracil (5-FU) (unpublished data), and by O’Neill
1975) with cytarabine [85]. Further, the multinucleated cells
ave a large cell volume, making them more susceptible to
hysical agitation [73].
Preferential damage of malignant cells is facilitated by
he fact that normal cells exposed to cytochalasin B exit the
ell cycle and enter the G0 state until sufficient actin levels
re restored [69]. Therefore, only malignant cells that have
ost the ability to enter this resting state become enlarged
nd multinucleated, providing an ideal target for sonication.
o put the size differentials into perspective, normal eryth-
ocytes are typically between 6 and 8 m and leukocytes
ange between 10 and 15 m (the occasional macrophage
rows up to 20 m) [73]. By contrast, cytochalasin B-treated
937 monocytic leukaemia cells routinely grow in excess of
0 m with some reaching nearly 40 m in diameter after
nough exposure [69]. These cells have reduced cytoskeletal
ntegrity and are ideal targets for sonication. As demonstrated
y my laboratory, U937 cells enlarged and multinucle-
ted through administration of 1.5 M cytochalasin B for
8 h are much more sensitive to low frequency (23.5 kHz)
r
d
t
Pltrasound than untreated U937 cells, and substantially
ore sensitive than normal hHSCs and human leukocytes
69].
Cytochalasin B also appears to have a considerable influ-
nce on mitochondrial activity. When U937 cells were
xposed to the same concentration of cytochalasin B
1.5 M), the cells exhibited a 4-fold increase in comparison
o U937 cells of typical histology, as assessed by MTT assay
73]. Such a dramatic increase in metabolic rate inherently
uggests using mitochondrial-directed agents in tandem with
ytochalasin B during ultrasound treatments. Indeed, reactive
xygen species (ROS) agents often target the mitochondrial-
nduced apoptotic pathway of leukaemia cells [70,71,74],
roviding a viable method to develop synergistic treatments.
his approach could be further supported with nucleic acid-
irected agents, as cytochalasin B-treated U937 cells are
onsiderably multinucleated. It is very likely that only a sin-
le nucleus will have to undergo apoptosis in order to destroy
he malignant cell; having so many nuclei present greatly
ncreases the chances of this event.
.4.  The  utility  of  sound  energy:  sonodynamic  therapy
s. photodynamic  therapy
Activating chemotherapeutic agents through the use of an
utside energy source is not a novel concept. In fact, SDT
s extremely similar to PDT, a proven method that is cur-
ently being used in the clinical setting [86,87]. The major
ifference between SDT and PDT is the energy source used
o activate the chemotherapeutic agent (sound vs.  light). In
DT, light is used to excite porphyrins and other endogenous
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olecules that emit photoluminescent light after returning
o the ground state [88]. Such activity produces excess ROS
evels that inflict substantial damage on the cellular integrity
f malignant cells, eventually inducing apoptotic mecha-
isms.
While PDT has indeed been shown to be effective against
articular squamous carcinomas, the effective range of the
reatment does not extend far past the skin barrier [88]. Con-
equently, PDT has limited utility in cancer therapy. SDT uses
ltrasound that can easily penetrate deep tissue layers where
ome malignancies reside. Although it retains the ability to
roduce ROS in the form of sonoluminescent light, SDT does
o through inertial cavitation. When microbubbles implode,
hey give off substantial amounts of energy (in upwards of
000 K and 800 atm), a phenomenon that produces sonolumi-
escent light, subsequently leading to the production of ROS
69]. The energy released from microbubble implosion also
everely damages malignant cells through subsequent hydro-
ynamic shear forces, destroying cytoskeletal structures of
ells and tumour vasculature [69].
Although PDT can effectively activate ROS agents
nd other species dependent on a light-activating source,
ytoskeletal alterations and perturbed tumour vasculature
etworks have not been observed. Therefore, PDT is also
imited in the variety of sensitizing agents that are available.
y contrast, ultrasound provides a source of physical per-
urbation that can be further enhanced when combined with
ytoskeletal-directed agents. My laboratory has shown that
icrofilament- or microtubule-disrupting agents (cytocha-
asin B and vincristine, respectively) produce higher rates
f neoplastic cell lysis than either the corresponding sta-
ilizing agents (jasplakinolide and paclitaxel, respectively)
r untreated cells when combined with low frequency
ltrasound (20 and 23.5 kHz, unpublished data). Further,
here exists the potential of combining microfilament- and
icrotubule-disrupting agents in combination with ultra-
ound to further damage malignant cell populations, as
ytochalasin B and vincristine demonstrate considerable drug
ynergy [89].
.  Conclusion
The inherent metastasis of leukaemia is apparent, as it
s derived from leukocytes that are designed to cover vast
istances in the human body in a very short amount of
ime. While carcinomas and other cancers must acquire spe-
ific mutations to gain this profound mobility, leukaemias
eed only become tumourigenic before being defined as
 metastatic disease. Without having the need to develop
utations that permeate invasion and migration, followed by
ntravasation, these haematological malignancies are free to
irculate throughout the body as malignant growths. Further,
eukocytes have an innate form of extravasation, suggesting
t is less complicated for dedifferentiated blasts to escape the
irculatory system. While leukaemias do not form primary
s
t
c
agy/Hematology 94 (2015) 149–163 161
umours, they are capable of rapidly crowding out healthy
lood cells as their unchecked growth sequesters valuable
esources. Eventually, the patient’s immune system will
ecome entirely compromised as healthy leukocytes have
een replaced by a sludge of white, dedifferentiated cells,
he hallmark that gave leukaemia its name (“leukos haima”
s white blood in Greek). Nevertheless, lymphoid leukaemias
ave the propensity to form secondary tumours once enough
utations have been acquired (Richter’s syndrome), which
ave very similar characteristics to lymphomas. It should also
e noted that myeloid leukaemias have been found to form
olid tumors, referred to as myeloid sarcomas, but these are
nrelated to lymphomas.
However, the most beneficial phenotypic characteristics
f leukaemia can be exploited by novel chemotherapeutic
pproaches. Specifically, SDT is capable of sonicating the
irculatory highway that leukaemic blasts use to migrate
owards distant tissue sites. Ultrasound can be used in com-
ination with chemotherapeutic agents that substantially
mplify the preferential damage inflicted on malignant cells.
s indicated by experimental evidence, ultrasonic waves
roduce remarkable antitumour effects under appropriate
onditions. However, such effects are not always widespread
nd varying levels of resistance are observed [69]. That is why
DT is such a sensible prospect, as it significantly enhances
he efficacy of sonication, while still demonstrating prefer-
ntial damage towards malignant cells. Every mechanism by
hich ultrasound destroys malignant tissue can in fact be
mplified when an appropriate sonosensitizer is administered
69]. Such drugs often attack cells through multiple mech-
nisms as well, creating a potential synergistic effect when
onosensitizers of different classes are used in combination.
t has even been shown to reverse acquired drug resistance in
ultiple cell lines, mitigating one of the most prolific defense
echanisms of cancer.
That is not to say all of the efforts put into developing
DT should be directed towards leukaemia, as there are other
alignancies that take the lives of many more individuals
ach year. In fact, SDT could serve a tremendous utility in
he clinic by eradicating metastatic emboli and micrometas-
ases of other cancer types. Doing so might dramatically delay
etastatic growths from forming in the patient, allowing cli-
icians to focus on the primary tumour, which can be treated
ith known adjuvant or neoadjuvant therapeutic approaches
pending on the performance status of the patient). It just
hould be noted that SDT has found particular promise with
eukaemia and that many lives could be saved if effective
reatments are developed. At any rate, the idea of combining
ltrasound with drugs that amplify the ways in which it prefer-
ntially damages malignant cells is gaining more legitimacy
s successful studies have vindicated the potential of SDT.
y using the synergistic effects of ultrasound and sonosen-itizers, SDT is proving to be a viable treatment modality
hat has the capability to revolutionize the way in which
hemotherapy is administered in the clinical setting. Such
n approach exploits the inherent metastasis of leukaemia,
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urning implicitly advantageous phenotypic characteristics
nto a fatal flaw. However, further preclinical testing is still
equired before clinical evaluation is initiated. Only through
hese necessary studies will enough evidence be compiled to
onclude whether SDT has substantial clinical potential.
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